ConductScience.org, home

Comparison · NCT05513053-85b0e07b

Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: Number of Participants With Unsolicited AEs

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: Number of Participants With Unsolicited AEs. Trial comparisons, record NCT05513053-85b0e07b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05513053-85b0e07b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1450.120.174wilson
Risk in group 20.1810.1530.212wilson
Risk difference, group 1 minus group 2-0.0358-0.07590.0045newcombe hybrid score
Risk ratio, group 1 over group 20.8020.6261.03log
Odds ratio, group 1 over group 20.7690.5721.03log
Number needed to treat, for one fewer participant with the outcome on Cohort 1: Participants Aged 9 to 17 Years than on Cohort 2: Participants Aged 18 to 49 Years28from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Cohort 1: Participants Aged 9 to 17 YearsParticipants received a single IM injection of RIV4 0.5 mL on Day 1.93641OG000
Group 2Cohort 2: Participants Aged 18 to 49 YearsParticipants received a single IM injection of RIV4 0.5 mL on Day 1.119658OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Unsolicited AEs
Description
An AE was any untoward medical occurrence in a clinical investigation participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, that is, prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination.
Time frame
From Day 1 up to 28 days post-vaccination (up to Day 29)
Population
Analysis was performed on the Safety analysis set which included participants who received 1 dose of the study vaccine.

Source ClinicalTrials.gov

Trial

Title
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
NCT number
NCT05513053
Phases
PHASE3
Conditions
Influenza Immunization
Interventions
Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Results first posted
2024-05-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05513053-85b0e07b